Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03398655 · ClinicalTrials.gov registry record · Phase 3
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
A Phase 3 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT03398655: Completed Phase 3 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
NCT03398655 is a Phase 3 study that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 408 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03398655, a Phase 3 study, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Interventions
- DRUG VB-111 + Paclitaxel
- DRUG Placebo + Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2022-07-19 |
| Phase | Phase 3 |
What the finished NCT03398655 record still lists
NCT03398655 is an interventional study that assigns participants to a tested intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which VB-111 + Paclitaxel is the first listed.
NCT03398655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03398655 about?
NCT03398655 is a clinical study titled "A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)". The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
What is the current status of trial NCT03398655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2017-12-19. Estimated completion is 2022-07-19.
What interventions are being tested in trial NCT03398655?
The interventions under investigation include: VB-111 + Paclitaxel (DRUG), Placebo + Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03398655?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03398655's enrollment target sits among peer trials
408 911th of 2000 higher than 1,088 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI